Overall Survival (OS) as a Function of the Number of Therapeutic Lines in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors (WDpNET)

#831

Introduction: At least 9 therapeutic options are now available for unresectable WDpNET patients. Whether all lines can be administrated before tumor or toxic-related deaths is currently unknown.

Aim(s): The primary endpoint was to determine OS as a function of the number of therapeutic lines. Secondary endpoints were to determine cumulative toxicity as defined by the frequency of modified serious adverse events (mSAE) as a function of the number of lines.

Materials and methods: Patients with unresectable WDpNET treated between 1998 and 2010 at the Gustave Roussy were studied. Locoregional (TACE) and systemic lines including somatostatin analogs or interferon[48 patients], targeted therapies (sunitinib, everolimus)[46], PRRT[26], chemotherapies (dacarbazine-, streptozotocin-, oxaliplatin-based)[82] were counted. Cumulative toxicity was defined by mSAE, including permanent toxicity (persistent grade 2-5).

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Berdelou A, Malka D, Leboulleux S, Boige V, Chougnet C,

Keywords: pNets,